Nathalie Coutry

Nathalie Coutry

Auto-generated profile, based on publicly available information

Nathalie Coutry

Institute of Functional Genomics (IGF), University of Montpellier, CNRS, INSERM, Montpellier, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
NCNathalie Coutry
Nathalie Coutry
JNJulie Nguyen
Julie Nguyen
SSSalima Soualhi
Salima Soualhi
FGFrançois Gerbe
François Gerbe
VMVictoria Meslier
Victoria Meslier
PJPhilippe Jay
Philippe Jay
Gut microbiota imbalance (dysbiosis) is increasingly associated with pathological conditions, both within and outside the gastrointestinal tract. Intestinal Paneth cells are considered to be guardians of the gut microbiota, but the events linking Paneth cell dysfunction with dysbiosis remain unclear. We report a three-step mechanism for dysbiosis initiation. Initial alterations in Paneth cells, as frequently observed in obese and inflammatorybowel diseases patients, cause a mild remodeling of microbiota, with amplification of succinate-producing species. SucnR1-dependent activation of epithelial tuft cells triggers a type 2 immune response that, in turn, aggravates the Paneth cell defaults, promoting dysbiosis and chronic inflammation. We thus reveal a function of tuft cells in promoting dysbiosis following Paneth cell deficiency and an unappreciated essential role of Paneth cells in maintaining a balanced microbiota to prevent inappropriate activation of tuft cells and deleterious dysbiosis. This succinate–tuft cell inflammation circuit may also contribute to the chronic dysbiosis observed in patients.

26 February 2016 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
NCNorbert Chauvet
Norbert Chauvet
NRNicola Romanò
Nicola Romanò
AMAnne‐Cécile Meunier
Anne‐Cécile Meunier
EGEvelyne Galibert
Evelyne Galibert
PFPierre Fontanaud
Pierre Fontanaud
NCNathalie Coutry
Nathalie Coutry

2 February 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
NCNorbert Chauvet
Norbert Chauvet
NRNicola Romanò
Nicola Romanò
CLChrystel Lafont
Chrystel Lafont
AGAnne Guillou
Anne Guillou
EGEvelyne Galibert
Evelyne Galibert
NCNathalie Coutry
Nathalie Coutry
Angiogenesis contributes in multiple ways to disease progression in tumors and reduces treatment efficiency. Molecular therapies targeting Vegf signaling combined with chemotherapy or other drugs exhibit promising results to improve efficacy of treatment. Dopamine has been recently proposed to be a novel safe anti‐angiogenic drug that stabilizes abnormal blood vessels and increases therapeutic efficacy. Here, we aimed to identify a treatment to normalize tumoral vessels and restore normal blood perfusion in tumor tissue with a Vegf receptor inhibitor and/or a ligand of dopamine G protein‐coupled receptor D2 (D2R). Dopamine, via its action on D2R, is an endogenous effector of the pituitary gland, and we took advantage of this system to address this question. We have used a previously described Hmga2/T mouse model developing haemorrhagic prolactin‐secreting adenomas. In mutant mice, blood vessels are profoundly altered in tumors, and an aberrant arterial vascularization develops leading to the loss of dopamine supply. D2R agonist treatment blocks tumor growth, induces regression of the aberrant blood supply and normalizes blood vessels. A chronic treatment is able to restore the altered balance between pro‐ and anti‐angiogenic factors. Remarkably, an acute treatment induces an upregulation of the stabilizing factor Angiopoietin 1. An anti‐Vegf therapy is also effective to restrain tumor growth and improves vascular remodeling. Importantly, only the combination treatment suppresses intratumoral hemorrhage and restores blood vessel perfusion, suggesting that it might represent an attractive therapy targeting tumor vasculature. Similar strategies targeting other ligands of GPCRs involved in angiogenesis may identify novel therapeutic opportunities for cancer.

23 July 2024 in Gut Microbes
Verified
Journal Article
Open access
NCNathalie Coutry
Nathalie Coutry
IGImène Gasmi
Imène Gasmi
FHFabien Herbert
Fabien Herbert
PJPhilippe Jay
Philippe Jay
Symbiosis between the host and intestinal microbial communities is essential for human health. Disruption in this symbiosis is linked to gastrointestinal diseases, including inflammatory bowel diseases, as well as extra-gastrointestinal diseases. Unbalanced gut microbiome or gut dysbiosis contributes in multiple ways to disease frequency, severity and progression. Microbiome taxonomic profiling and metabolomics approaches greatly improved our understanding of gut dysbiosis features; however, the precise mechanisms involved in gut dysbiosis establishment still need to be clarified. The aim of this review is to present new actors and mechanisms underlying gut dysbiosis formation following parasitic infection or in a context of altered Paneth cells, revealing the existence of a critical crosstalk between Paneth and tuft cells to control microbiome composition.

1 June 2011
Verified
Book Chapter
Closed access
NCNorbert Chauvet
Norbert Chauvet
EGEvelyne Galibert
Evelyne Galibert
AMAnne-Cecile Meunier
Anne-Cecile Meunier
VRValerie Rigau
Valerie Rigau
GOGuillaume Osterstock
Guillaume Osterstock
NCNathalie Coutry
Nathalie Coutry
Article published by the Endocrine Society Article published by the Endocrine Society